Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

James R. Miller; Serigne Lo; Mehdi Nosrati; Jonathan R. Stretch; Andrew J. Spillane; Robyn P.M. Saw; Kerwin F. Shannon; Omgo E. Nieweg; Sydney Ch’ng; Kevin B. Kim; Stanley P. L. Leong; John F. Thompson; Richard A Scolyer; Mohammed Kashani–Sabet

doi:10.1001/jamanetworkopen.2023.6356

Abstract

1 min read

This prognostic study/decision analytical model found that the PCM approach outperformed conventional multiple logistic regression analysis in predicting which patients would have positive results on SLNB. These findings suggest that systematically producing and exploiting more accurate SLNB-positivity probabilities could improve the selection of patients with melanoma for SLNB compared with using established guidelines, thus improving the cost-effectiveness of the selection process. Eligibility guidelines to undergo SLNB should include a context-tailored minimum cutoff probability.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2011

Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma

Rajmohan Murali, Lauren E. Haydu, Michael J. Quinn, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson, Richard A Scolyer

Article2022

Sentinel lymph node biopsy rates in Victoria, 2018 and 2019

Caroline G. Watts, Andrew J. Spillane, Michael A. Henderson, Anne Ε. Cust, Jeffrey Braithwaite, DE Gyorki, AM Hong, Kelly Jw, GV Long, VJ Mar, AM Menzies, Rachael L. Morton, Frances Rapport, Rpm Saw, Helen Schmid, Richard A Scolyer, Al Smith, Abigail Winder, GJ Mann

Article2015

PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials.

Hojabr Kakavand, Ricardo E. Vilain, James S. Wilmott, Hazel Burke, Jennifer H. Yearley, John F. Thompson, Peter Hersey, Georgina V. Long, Richard A Scolyer

Article2023

Population-based validation of the melanoma institute australia (MIA) and the memorial sloan-kettering cancer center (MSKCC) predictive tool for sentinel node status in patients with melanoma.

Rasmus Mikiver, Roger Olofsson Bagge, Michael A. Marchetti, Alexander Christopher Jonathan Van Akkooi, Daniel G. Coit, Christian Ingvar, Karolin Isaksson, Richard A Scolyer, John F. Thompson, Alexander H. R. Varey, Johan Lyth, Edmund K. Bartlett

Letter2023

Knowledge of sentinel lymph node status improves accuracy when predicting melanoma mortality and selecting patients for adjuvant immunotherapy

Serigne Lo, Alexander H. R. Varey, Mary‐Ann El Sharouni, Richard A Scolyer, John F. Thompson